Major new scientific partnership between the UK and France to tackle cancer’s toughest challenges
New partnership
Today we’re announcing a major new €10m (£8.6m) partnership between Cancer Research UK and France’s Institut National Du Cancer (INCa) to help fund world-class researchers to take on cancer’s toughest challenges through the global Cancer Grand Challenges initiative.
Cancer Grand Challenges was founded in 2020 by two of the largest funders of cancer research in the world – Cancer Research UK and the National Cancer Institute (NCI) in the US*.
INCa’s participation in Cancer Grand Challenges will further expand the international reach of the initiative, bringing on board France’s foremost cancer research institute to take on cancer’s biggest challenges and deliver transformational research. INCa, one of Cancer Research UK’s key partners, is the first to pledge funds to support multiple teams in a single round of Cancer Grand Challenges, alongside the initiative’s original founding partners.
INCa’s €10m (£8.6m) investment will help to fund the next round of Cancer Grand Challenges teams. There are currently 12 shortlisted teams each competing for the chance to secure up to £20m for their global research projects in the latest round of challenges. Winning teams will be announced to the world in March 2024.
Cancer Grand Challenges brings together diverse international organisations, collaborators and research leaders who share in its mission. These include the Scientific Foundation of the Spanish Association Against Cancer, the Dutch Cancer Society, and The Mark Foundation for Cancer Research. To date, more than £210m has been invested in the Cancer Grand Challenges initiative, reflecting a shared commitment to supporting innovative, cross-disciplinary efforts to advance cancer research.
“With funding partners from the UK, USA, Spain, the Netherlands and now France, Cancer Grand Challenges is growing, ever steadily into a global leader in scientific collaboration and vital cancer research.
“INCa’s participation in Cancer Grand Challenges brings an exciting new opportunity for us to accelerate scientific discoveries and innovation on a scale which could not be achieved by the actions of one individual country or research institution alone.
“Through the support of INCa and Cancer Research UK’s other global partners, our international teams will be given the freedom to think differently, act creatively and take on some of the toughest challenges in cancer.”
“Cancers with a poor prognosis are a major public health challenge which we need to address with the kind of breakthrough science that Cancer Grand Challenges supports through the mobilisation of world-class investigators and teams.
“We've seen science reach new frontiers through comparable initiatives in the world of physics, and cancer research is now on the verge of experiencing a similar evolution.
“INCa is fully committed to international scientific collaborations in cancer research, as part of our 10-year cancer control strategy. This major partnership between INCa and Cancer Research UK strengthens the Institute's global actions in the fight against cancer.
Separately, in May this year, we also joined the G7 Cancer initiative** alongside 6 of the most advanced international organisations who are fighting the disease."
Notes
Notes
*The National Cancer Institute leads the NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. The National Cancer Institute’s contributions to Cancer Grand Challenges are fully funded by the U.S. government.
**G7 Cancer officially launched on May 9. Bringing together the organisations at the forefront of the fight against cancer, this group aims to strengthen cooperation between partners to accelerate the fight against the disease, and in particular to address the most complex challenges. At the first meeting, which was held at May 9, the organisations' representatives signed a Memorandum of Understanding to set the cooperation framework.
The G7 partner organisations are: Cancer Australia; Canadian Institute of Health Research; National Cancer Institute, France; German Cancer Research Center; National Cancer Center, Japan; Cancer Research UK; US Department of Health and Human Services, National Cancer Institute .